» Articles » PMID: 31384418

Management of Diabetes Complications in Youth

Overview
Specialty Endocrinology
Date 2019 Aug 7
PMID 31384418
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Type 1 and type 2 diabetes are increasing in prevalence and diabetes complications are common. Diabetes complications are rarely studied in youth, despite the potential onset in childhood. Microvascular complications of diabetes include retinopathy, diabetic kidney disease or nephropathy, and neuropathy that may be somatic or autonomic. Macrovascular disease is the leading cause of death in patients with type 1 diabetes. Strict glycaemic control will reduce microvascular and macrovascular complications; however, they may still manifest in youth. This article discusses the diagnosis and treatment of complications that arise from type 1 and type 2 diabetes mellitus in youth. Screening for complications is paramount as early intervention improves outcome. Screening should commence from 11 years of age depending on the duration of type 1 diabetes or at diagnosis for patients with type 2 diabetes. Diabetic retinopathy may require invasive treatment such as laser therapy or intravitreal antivascular endothelial growth factor therapy to prevent future blindness. Hypertension and albuminuria may herald diabetic nephropathy and require management with angiotensin converting enzyme (ACE) inhibition. In addition to hypertension, dyslipidaemia must be treated to reduce macrovascular complications. Interventional trials aimed at examining the treatment of diabetes complications in youth are few. Statins, ACE inhibitors and metformin have been successfully trialled in adolescents with type 1 diabetes with positive effects on lipid profile, microalbuminuria and measures of vascular health. Although relatively rare, complications do occur in youth and further research into effective treatment for diabetes complications, particularly therapeutics in children in addition to prevention strategies is required.

Citing Articles

D1S-Neuro Program: Frequency and Risk Factors for the Development of Diabetic Neuropathy in Pediatric Patients with Type 1 Diabetes Mellitus, a Single Center Study.

Piccoli M, Gutierrez De Rubalcava Doblas J, Furlan P, Cocchio S, Zamberlan A, Panzeri G Biomedicines. 2025; 13(1.

PMID: 39857602 PMC: 11762328. DOI: 10.3390/biomedicines13010019.


Promising predictors of diabetic peripheral neuropathy in children and adolescents with type 1 diabetes mellitus.

Abo Hola A, Abd El Naby S, Allam E, Gab Allah A, Hammad D Ital J Pediatr. 2024; 50(1):215.

PMID: 39402605 PMC: 11479551. DOI: 10.1186/s13052-024-01774-y.


Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes.

Sridhar V, Limonte C, Groop P, Heerspink H, Pratley R, Rossing P Diabetologia. 2023; 67(1):3-18.

PMID: 37801140 DOI: 10.1007/s00125-023-06015-1.


Latent classifications of parental involvement in diabetes management for youth with type 1 diabetes: A randomized clinical trial.

Temmen C, Lu R, Gee B, Chen Z, Nansel T Pediatr Diabetes. 2022; 23(7):1133-1142.

PMID: 36250647 PMC: 11090373. DOI: 10.1111/pedi.13397.


Clinical Utility and Outcome Prediction of Early ZnT8-IgG Testing and Titer in Type 1 Diabetes.

Dahl A, M S, Pittock S, Pittock S J Clin Res Pediatr Endocrinol. 2022; 15(1):35-41.

PMID: 35984226 PMC: 9976167. DOI: 10.4274/jcrpe.galenos.2022.2022-4-16.


References
1.
Stratton I, Adler A, Neil H, Matthews D, Manley S, Cull C . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321(7258):405-12. PMC: 27454. DOI: 10.1136/bmj.321.7258.405. View

2.
White N, Cleary P, Dahms W, Goldstein D, Malone J, Tamborlane W . Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr. 2001; 139(6):804-12. DOI: 10.1067/mpd.2001.118887. View

3.
Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D . Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care. 2002; 26(1):138-43. DOI: 10.2337/diacare.26.1.138. View

4.
Perkins B, Ficociello L, Silva K, Finkelstein D, Warram J, Krolewski A . Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003; 348(23):2285-93. DOI: 10.1056/NEJMoa021835. View

5.
Aiello L . Perspectives on diabetic retinopathy. Am J Ophthalmol. 2003; 136(1):122-35. DOI: 10.1016/s0002-9394(03)00219-8. View